DRKS00014698尚未招募不适用

Pathophysiology of respiratory muscle stength and its contribution to exercise intolerance in patients with congenital heart disease

Institut für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster0 个研究点目标入组 60 人开始时间: 2018年6月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•a. Age > 18 years (no age limit) (Group 1, 2 and 3)
•b. able to consent (Group 1, 2 and 3)
•c. Diagnosis of congenital heart disease according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of congenital heart disease has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy for pulmonary arterial Hypertension due to congenital heart disease; where there was no treatment with combination therapy in PAH patients then the reason must be documented
•d. Controls (matched for age and gender) with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone

•a. Body Mass Index (BMI) > 35
•b. Chronic obstructive pulmonary disease, emphysema
•c. Presence of severe neurological comorbidities especially primary myopathy, muscular dystrophy, motor neuron disease, phrenic nerve disease, epilepsy, multiple sclerosis, parkinson’s disease
•d.Severe psychiatric disease including dementia
•e. Cardiac pacemaker

发起方

Institut für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster